Literature DB >> 16156629

Tuning of redox properties for the design of ruthenium anticancer drugs: part 2. Syntheses, crystal structures, and electrochemistry of potentially antitumor [Ru III/II Cl6-n(Azole)n]z(n = 3, 4, 6) complexes.

Erwin Reisner1, Vladimir B Arion, Anna Eichinger, Norbert Kandler, Gerald Giester, Armando J L Pombeiro, Bernhard K Keppler.   

Abstract

A series of mixed chloro-azole ruthenium complexes with potential antitumor activity, viz., mer-[RuIIICl3(azole)3] (B), trans-[RuIIICl2(azole)4]Cl (C), trans-[RuIICl2(azole)4] (D), and [RuII(azole)6](SO3CF3)2 (E), where azole = 1-butylimidazole (1), imidazole (2), benzimidazole (3), 1-methyl-1,2,4-triazole (4), 4-methylpyrazole (5), 1,2,4-triazole (6), pyrazole (7), and indazole (8), have been prepared as a further development of anticancer drugs with the general formula [RuCl4(azole)2]- (A). These compounds were characterized by elemental analysis, IR spectroscopy, electronic spectra, electrospray mass spectrometry, and X-ray crystallography. The electrochemical behavior has been studied in detail in DMF, DMSO, and aqueous media using cyclic voltammetry, square wave voltammetry, and controlled potential electrolysis. Compounds B and a number of C complexes exhibit one RuIII/RuII reduction, followed, at a sufficiently long time scale, by metal dechlorination on solvolysis. The redox potential values in organic media agree with those predicted by Lever's parametrization method, and the yet unknown EL parameters were estimated for 1 (EL = 0.06 V), 3 (EL = 0.10 V), 4 (EL = 0.17 V), and 5 (EL = 0.18 V). The EL values for the azole ligands 1-8 correlate linearly with their basicity (pK(a) value of the corresponding azolium acid H2L+). In addition, a logarithmic dependence between the homogeneous rate constants for the reductively induced stepwise replacement of chloro ligands by solvent molecules and the RuIII/RuII redox potentials was observed. Lower E(1/2) values (higher net electron donor character of the ligands) result in enhanced kinetic rate constants of solvolysis upon reduction. The effect of the net charge on the RuIII/RuII redox potentials in water is tentatively explained by the application of the Born equation. In addition, the pH-dependent electrochemical behavior of trans-[RuCl2(1,2,4-triazole)4]Cl is discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16156629     DOI: 10.1021/ic0503737

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  7 in total

1.  Synthesis and Characterization of Novel Ruthenium(III) Complexes with Histamine.

Authors:  Jakob Kljun; Sasa Petricek; Dusan Zigon; Rosana Hudej; Damijan Miklavcic; Iztok Turel
Journal:  Bioinorg Chem Appl       Date:  2010-06-02       Impact factor: 7.778

2.  Electronic structural investigations of ruthenium compounds and anticancer prodrugs.

Authors:  Travis V Harris; Robert K Szilagyi; Karen L McFarlane Holman
Journal:  J Biol Inorg Chem       Date:  2009-04-07       Impact factor: 3.358

3.  En route to osmium analogues of KP1019: synthesis, structure, spectroscopic properties and antiproliferative activity of trans-[Os(IV)Cl4(Hazole)2].

Authors:  Gabriel E Büchel; Iryna N Stepanenko; Michaela Hejl; Michael A Jakupec; Bernhard K Keppler; Vladimir B Arion
Journal:  Inorg Chem       Date:  2011-07-08       Impact factor: 5.165

4.  Transfer Hydrogenation and Antiproliferative Activity of Tethered Half-Sandwich Organoruthenium Catalysts.

Authors:  Feng Chen; Isolda Romero-Canelón; Joan J Soldevila-Barreda; Ji-Inn Song; James P C Coverdale; Guy J Clarkson; Jana Kasparkova; Abraha Habtemariam; Martin Wills; Viktor Brabec; Peter J Sadler
Journal:  Organometallics       Date:  2018-04-23       Impact factor: 3.876

5.  Cytotoxic (salen)ruthenium(iii) anticancer complexes exhibit different modes of cell death directed by axial ligands.

Authors:  Cai Li; Kwok-Wa Ip; Wai-Lun Man; Dan Song; Ming-Liang He; Shek-Man Yiu; Tai-Chu Lau; Guangyu Zhu
Journal:  Chem Sci       Date:  2017-07-31       Impact factor: 9.825

6.  Antineoplastic activity of a novel ruthenium complex against human hepatocellular carcinoma (HepG2) and human cervical adenocarcinoma (HeLa) cells.

Authors:  Carlos Eduardo Alves de Souza; Amanda do Rocio Andrade Pires; Carolina Riverin Cardoso; Rose Maria Carlos; Silvia Maria Suter Correia Cadena; Alexandra Acco
Journal:  Heliyon       Date:  2020-05-06

7.  The Ruthenium Nitrosyl Moiety in Clusters: Trinuclear Linear μ-Hydroxido Magnesium(II)-Diruthenium(II), μ3-Oxido Trinuclear Diiron(III)-Ruthenium(II), and Tetranuclear μ4-Oxido Trigallium(III)-Ruthenium(II) Complexes.

Authors:  Iryna Stepanenko; Pavlo Mizetskyi; Ewelina Orlowska; Lukáš Bučinský; Michal Zalibera; Barbora Vénosová; Martin Clémancey; Geneviève Blondin; Peter Rapta; Ghenadie Novitchi; Wolfgang Schrader; Dominik Schaniel; Yu-Sheng Chen; Martin Lutz; Jozef Kožíšek; Joshua Telser; Vladimir B Arion
Journal:  Inorg Chem       Date:  2021-12-28       Impact factor: 5.165

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.